Antileukotrienes in the treatment of asthma and allergic rhinitis

Jornal de Pediatria

Volumn 82, Issue SUPPL. 2, 2006, Pages

  Ribeiro, Jose Dirceu ^a,b,c,d   Toro, Adyléia A D C ^a   Baracat, Emilio C E ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Sociedade Brasileira de Pediatria e Sociedade Brasileira de Pneumologia e Tisiologia   (Brazil)

^c Este Trabalho Foi Parcialmente Financiado Pela CAPES   (Brazil)

^d Cidade Universitária Zeferino Vaz   (Brazil)

Author keywords

Antileukotrienes; Asthma; Exercise induced asthma; Montelukast; Rhinitis; Zafirlukast

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; FLUTICASONE; KETOTIFEN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MONTELUKAST; NEDOCROMIL; PLACEBO; PRANLUKAST; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; ZAFIRLUKAST; ZILEUTON;

ABDOMINAL PAIN; ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG POTENTIATION; DRUG TRANSPORT; GROWTH DISORDER; HEADACHE; HOSPITALIZATION; HUMAN; LENGTH OF STAY; META ANALYSIS; MONOTHERAPY; NAUSEA; OTITIS; PHARYNGITIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URTICARIA; VIRAL BRONCHIOLITIS; WHEEZING;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; ASTHMA, EXERCISE-INDUCED; CHILD; DRUG THERAPY, COMBINATION; HUMANS; INFANT; LEUKOTRIENE ANTAGONISTS; LEUKOTRIENES; MEMBRANE PROTEINS; RECEPTORS, LEUKOTRIENE; RESPIRATORY SYSTEM; RHINITIS; TREATMENT OUTCOME;

EID: 33845731373     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1553     Document Type: Review

References (55)

1. Bisgaard H, Szefler S. Long-acting beta2 agonists and paediatric asthma. Lancet. 2006;367: 286-8.
2. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention NHLBI/WHO workshop report. Updated 2005. http://www.ginasthma.org/Guidelineitem.asp??l1=2&l2=1&intId=60. Access: 17/09/2006.
3. British Thoracic Society; Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Thorax. 2003;58 Suppl 1:i1-94.
4. National Institutes of Health. (NIH) National Asthma Education and Prevention Program. Guidelines for diagnosis and management of asthma. Publication No. 97-4051, 1997. Updated 2002. http://www.nhlbi.nih.gov/ guidelines/asthma/asthgdln.htm. Access: 17/09/2006.
5. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of β-agonists in patients with asthma and COPD: a metaanalysis. Chest. 2004;125:2309-21.
6. Bisgaard H. Long-acting 2-agonists in management of childhood asthma: a critical review of the literature. Pediatr Pulmonol. 2000;29:221-34.
7. Bisgaard H. Effect of long-acting 2-agonists on exacerbation rates of asthma in children. Pediatr Pulmonol. 2003;36:391-8.
8. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003;124:70-4.
9. Wooltorton E. Long-acting B2 agonists in asthma: safety concerns. CMAJ. 2005;173:1030-1.
10. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. Is there a problem with inhaled long-acting b-adrenergic agonists? J Allergy Clin Immunol. 2006;117:3-16.
11. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM, SMART Study Group. The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26.
12. Martinez FD. Safety of long-acting beta-agonists - an urgent need to clear the air. N Engl J Med. 2005;353:2637-9.
13. Walia M, Lodha R, Kabra SK. Montelukast in pediatric asthma management. Indian J Pediatr. 2006;73:275-82.
14. Langlois A, Ferland C, Tremblay GM, Laviolette M. Montelukast regulates eosinophil protease activity through a leukotriene-independent mechanism. J Allergy Clin Immunol. 2006;118:113-9.
15. Hay DW, Torphy TJ, Undem BJ. Cysteinyl leukotrienes in asthma: old mediators up to new tricks. Trends Pharmacol Sci. 1995,16:304-9.
16. Zeidler MR, Kleerup EC, Goldin JG, Kim HJ, Truong DA, Simmons MD, et al. Montelukast improves regional air-trapping. due to small airways obstruction in asthma. Eur Respir J. 2006;27:307-15.
17. Spahn JD, Covar RA, Jain N, Gleason M, Shimamoto R, Szefler SJ, et al. Effect of montelukast on peripheral airflow obstruction in children with asthma. Ann Allergy Asthma Immunol. 2006;96:541-9.
18. Nieto A, Pamiesa R, Olivera F, Medinab A, Caballeroa L, Mazon A. Montelukast improves pulmonary function measured by impulse oscillometry in children with asthma (Mio study). Respir Med. 2006;100:1180-5.
19. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J. 1999;14:12-8.
20. Laviolette M, Malmstrom K, Lu S, Chervinsky P, Pujet JC, Peszek I, et al. Montelukast added to inhaled beclomethasone in treatment of asthma. Montelukast/Beclomethasone Additivity Group. Am J Respir Crit Care Med. 1999;160:1862-8.
21. Lex C, Zacharasiewicz A, Payne DN, Wilson NM, Nicholson AG, Kharitonov SA, et al. Exhaled breath condensate cysteinyl leukotrienes and airway remodeling in childhood asthma: a pilot study. Respir Res. 2006;7:63.
22. O'Shaughnessy KM, Wellings R, Gillies B, Fuller RW. Differential effects of fluticasone propionate on allergen-evoked bronchoconstriction and increased urinary leukotriene E4 excretion. Am Rev Respir Dis. 1993;147:1472-6.
23. Pavord ID, Ward R, Woltmann G, Wardlaw AJ, Sheller JR, Dworski R. Induced sputum eicosanoid concentrations in asthma. Am J Respir Crit Care Med. 1999;160:1905-9.
24. Straub DA, Moeller A, Minocchieri S, Hamacher J, Sennhauser FH, Hall GL, et al. The effect of montelukast on lung function and exhaled nitric oxide in infants with early childhood asthma. Eur Respir J. 2005;25:289-94.
25. Bisgaard H, Zielen S, Garcia-Garcia ML, Johnston SL, Gilles L, Menten J, et al. Montelukast reduces asthma exacerbations in 2-to 5-year-old children with intermittent asthma. Am J Respir Crit Care Med. 2005;171:315-22.
26. Knorr B, Franchi LM, Bisgaard H, Vermeulen JH, LeSouef P, Santanello N, et al. Montelukast, a leukotriene receptor antagonist, for the treatment of persistent asthma in children aged 2 to 5 years. Pediatrics. 2001;108;E48.
27. Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics. 2005,116:360-9.
28. Ng D, Salvio F, Hicks G. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev. 2004;(2):CD002314.
29. Ducharme FM, Di Salvio F. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children (Cochrane Review). The Cochrane Database of Systematic Reviews 2004, Issue 1. Art. No.: CD002314. DOI:10.1002/14651858.CD002314.
30. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115:233-42.
31. Zeiger RS, Szefler SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, et al. Childhood asthma research and education network of the National Heart, Lung, and Blood Institute. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol. 2006;117:45-52.
32. Vaquerizo MJ, Casan P, Castillo P, Perpina P, Sanchis J, Sobradillo V, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003;58:204-10.
33. Price DB, Hernandez D, Magyar P, Fiterman J, Beeh KM, James IG, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58:211-6.
34. Ducharme F, Schwartz Z, Hicks G, Kakuma R. Addition of antileukotriene agents to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. 2004;(2):CD003133.
35. Bjermer L, Bisgaard H, Bousquet J, M Fabbri LM, Greening AP, Haahtela T, et al. Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial. BMJ. 2003;327:891-7.
36. Bjermer L, Bisgaard H, Bousquet J, Fabbri LM, Greening A, Haahtela T, et al. Montelukast or salmeterol combined with an inhaled steroid in adult asthma: design and rationale of a randomized, double-blind comparative study (the IMPACT Investigation of Montelukast as a Partner Agent for Complementary Therapy-trial). Respir Med. 2000;94:612-21.
37. Ringdal N, Eliraz A, Pruzinec R, Weber HH, Mulder PG, Akveld M, et al. The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma. Respir Med. 2003;97:234-41.
38. Ram FS, Cates CJ, Ducharme FM. Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. 2005;25:CD003137.
39. Harmanci K, Bakirtas A, Turktas I, Degim T. Oral montelukast treatment of preschool-aged children with acute asthma. Ann Allergy Asthma Immunol. 2006;96:731-5.
40. Rodrigo GJ, Yañez A. The role of antileukotriene therapy in seasonal allergic rhinitis: a systematic review of randomized trials. Ann Allergy Asthma Immunol. 2006;96:779-86.
41. Peters-Golden M, Henderson WR Jr. The role of leukotrienes in allergic rhinitis. Ann Allergy Asthma Immunol. 2005;94:609-18.
42. Volovitz B, Welliver RC, De Castro G, Krystofik DA, Ogra PL. The release of leukotrienes in the respiratory tract during infection with respiratory syncytial virus: role in obstructive airway disease. Pediatr Res. 1988;24:504-7.
43. Volovitz B, Faden H, Ogra PL. Release of leukotriene C4 in respiratory tract during acute viral infection. J Pediatr. 1988;112:218-22.
44. van Schaik SM, Tristram DA, Nagpal IS, Hintz KM, Welliver RC 2nd, Welliver RC. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol. 1999;103:630-6.
45. Bisgaard H; Study Group on Montelukast and Respiratory Syncytial Virus. A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med. 2003;167:379-83.
46. Wedde-Beer K, Hu C, Rodriguez MM, Piedimonte G. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol. 2002;282:L1143-50.
47. Harmanci K, Bakirtas A, Turktas I, Degim T. Oral montelukast treatment of preschool-aged children with acute asthma. Ann Allergy Asthma Immunol. 2006;96:731-5.
48. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354:1985-97.
49. Becker AB, Kuznetsova O, Vermeulen J, Soto-Quiros ME, Young B, Reiss TF, et al. Linear growth in prepubertal asthmatic children treated with montelukast, beclomethasone, or placebo: a 56-week randomized double-blind study. Ann Allergy Asthma Immunol. 2006;96:800-7.
50. Reiss TF, Hill JB, Harman E, Zhang J, Tanaka WK, Bronsky E, et al. Increased urinary excretion of LTE4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax. 1997;52:1030-5.
51. Peroni DG, Piacentini GL, Ress M, Bodini A, Loiacono A, Aralla R, et al. Time efficacy of a single dose of montelukast on exercise-induced asthma in children. Pediatr Allergy Immunol. 2002;13:434-7.
52. Pajaron-Fernandez M, Garcia-Rubia S, Sanchez-Solis M, Garcia-Marcos L. Montelukast administered in the morning or in the evening to prevent exercise induced bronchoconstriction in children. Pediatric Pulmonol. 2006;41:222-7.
53. Melo RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in children: montelukast attenuates the immediate phase and late phase responses. J Allergy Clin Immunol. 2003;111:301-17.
54. de Benedictis FM, del Giudice MM, Forenza N, Decimo F, de Benedictis D, Capristo A. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J. 2006;28:291-5.
55. Green JJ, Weinberg EG. Problems in the management of asthma in young children: a potential role for montelukast. SAMJ. 2004;94:746-8.